About Entirely Well
Entirely Well develops microbiome-safe formulas built into daily essentials. The aim is to help prevent yeast infections and bacterial vaginosis instead of treating them after they occur. The company is advancing a personal lubricant that is under FDA review as a Class II medical device. Its products are still in development and not yet for sale.
Reilly Williams is the founder and chief executive officer. She is a former manager at Tesla and Rivian. The company is based in Denver, Colorado. Its team page also names Gordon Rogers and Jessica Heilman, and an advisory board of Kevin Noble, Jennifer Virro and Avril Louise Clarke. The company has 6 retail letters of intent and 3 from women's sports teams.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 8, 2025 | Oct 23, 2026 | $230,000target not set | 3 | $76,667 | OptionsRule 506(b) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Entirely Well
Entirely Well Inc. is a Denver company developing daily personal care products meant to prevent yeast infections and bacterial vaginosis. The products are still in development and not yet for sale. The company has an open seed round, a state grant and two accelerator programs behind it.
The problem it targets
After leaving a corporate job and facing medical issues, Reilly Williams saw a gap for women trying to prevent vaginal infections. In her account, the only options were to change daily habits on a doctor's advice or take oral supplements, which people tend to forget. Entirely Well's investor page cites 46 million US women affected each year. It also cites a 40 percent recurrence rate that requires antibiotics several times a year. It puts spending on reactive treatments at $4.8 billion a year and calls those treatments ineffective.
What the product does
Williams created formulas for daily use, so protection does not depend on remembering a supplement. The design goal is preventive health without harming the microbiome. An Athletes section describes new locker room protocols meant to keep athletes in the game. The investor page lists a target gross margin of 73 percent.
Progress so far
The company has more than 750 email subscribers and more than 7,000 social followers, all organic. Its 2026 newsletter headlines point to clinical success and a key leadership hire in July. They also mention European expansion and market work, and federal grants. The site gives no further detail on those items.
Who backs it
The State of Colorado awarded the company a $250,000 grant, with a 2:1 match due by February 2026. The company graduated from the Gener8tor gBeta and Innosphere accelerators. A June 2026 newsletter headline mentions closing its pre-seed round, and an October 2026 headline mentions new capital. A seed round is now open. The company has not named individual investors.
How the market is moving
Entirely Well's case is that antibiotic resistance is making usual treatments fail, so prevention should replace reactive care. Its investor page sizes the US market for yeast and BV products at $18.1 billion. It puts over-the-counter feminine care at $6 billion and its target market of chronic sufferers at $625 million. It lists Honey Pot at $380 million, Maven at $1 billion and Queen V (undisclosed exit) as recent comparables. In a LinkedIn post shown on its site, the company writes that only 1 percent of healthcare R&D funding goes to female-specific conditions beyond cancer.
We wrote this summary from public statements by Entirely Well and its investors. It is not investment advice.
Entirely Well in the News
Leadership Team
Executive officers and directors listed on Entirely Well's Form D filed Oct 23, 2026.